Press releaseGlobe Newswire
Apollomics
APLMW · NASDAQ
$0.0112+$0.0003 (+2.75%)TodayMarket closed ·
Prev close $0.0109
Latest news
- Press releaseGlobe Newswire
Nasdaq Resumes Trading in Apollomics Inc.
- Press releaseGlobe Newswire
Apollomics, Inc. Company Operational Continuity Update
- Press releaseGlobe Newswire
Nasdaq Halts Apollomics Inc., Ltd.
- Press releaseGlobe Newswire
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
- Press releaseGlobe Newswire
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
- Press releaseGlobe Newswire
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
- Press releaseGlobe Newswire
Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
- Press releaseGlobe Newswire
Apollomics' Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
- Press releaseGlobe Newswire
Apollomics Presents Vebreltinib Data in Patients with Non-Small Cell Lung Cancer with METex14 Skipping Mutations at European Society for Medical Oncology (ESMO) Congress 2024
- Press releaseGlobe Newswire
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
- Press releaseGlobe Newswire
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.